SUP - As Supernus acquires Adamis other Parkinson's players mixed on the day

Other biotech companies working on Parkinson's disease closed mixed after Supernus Pharmaceuticals' (NASDAQ:SUPN) morning announcement of an up to $850M deal to acquire Adamas Pharmaceuticals (NASDAQ:ADMS), strengthening the former's Parkinson's portfolio. Supernus closed up 7.8%, while Adamas ended the day up 75%. Denali Therapeutics (NASDAQ:DNLI) fell about 7.5%. The company has DNL151, an inhibitor of leucine-rich repeat kinase 2 (LRRK2), in phase 1 in partnership with Biogen (NASDAQ:BIIB). Biogen, down 0.1%, has another LRRK2 in development, BIIB094, also in phase 1, in collaboration with Ionis Pharmaceuticals (NASDAQ:IONS). It also has BIIB118 in phase 1 for irregular sleep wake disorder in Parkinson's. Sage Therapeutics (NASDAQ:SAGE) closed up 0.4%. SAGE-718 is in phase 1 for mild cognitive impairment due to Parkinson's. Annovis Bio closed up 1.5%. Last week, shares jumped after the company released phase 2 results on ANVS401.

For further details see:

As Supernus acquires Adamis, other Parkinson's players mixed on the day